The BEND7 Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-mediated gene disruption model in which the BEND7 locus has been targeted across a heterogeneous cell population. This polyclonal format preserves the diversity of editing events, avoiding the artifacts that can arise from single-cell clonal selection, and yields a robust loss-of-function system. Researchers can employ these cells to investigate the downstream molecular and phenotypic consequences of BEND7 ablation in a human cervical adenocarcinoma context.
The host HeLa cell line, an HPV18-positive cervical adenocarcinoma epithelial model, was originally established from Henrietta Lacks in 1951. As one of the most extensively utilized immortalized human cell lines, HeLa offers a well-characterized genetic background, rapid proliferation, and exceptional suitability for protein expression and functional genomics assays. Its history in cancer research and chromatin biology provides a robust framework for integrating new functional data on transcriptional regulators like BEND7.
BEND7 belongs to the BEN domain family of transcriptional regulators, characterized by a conserved DNA-binding domain. It is predicted to function as a repressor by recruiting co-repressor complexes to chromatin, thereby silencing gene expression. Knockout of BEND7 derepresses target genes, facilitating the identification of downstream effectors and repressive complex components. Although interacting partners are unknown, the BEN domain??s structural relation to chromatin-organizing modules suggests potential roles in genome architecture.
Within HeLa cells, the BEND7 knockout provides a valuable tool for dissecting transcriptional repression in the context of an HPV-transformed cervical carcinoma. While no strong disease associations have been established for BEND7, its putative function as a chromatin regulator implicates it in the control of genes governing proliferation and differentiation. This model enables direct assessment of how loss of a repressive factor reshapes the transcriptome of a widely studied cancer cell line, potentially revealing novel vulnerabilities or regulatory nodes.
Comprehensive analysis of BEND7 function is facilitated by a suite of compatible assays. Western blotting confirms the absence of BEND7 protein, while RT-qPCR and RNA-sequencing quantify the transcriptional response and identify derepressed gene networks. Proliferation assays and flow cytometry evaluate growth alterations and cell-cycle perturbations, and co-immunoprecipitation experiments seek to capture BEND7-containing protein complexes. These polyclonal knockout cells thus serve as a versatile platform for mapping the BEND7 regulatory landscape and its contributions to cervical cancer cell biology. For ordering and technical support, contact Ascent Research.
